levokabast n | Tizin Alergi nasal spray 50 mcg / dose of 10 ml
Special Price
$20.37
Regular Price
$28.00
In stock
SKU
BID471424
Release form
Dosage nasal spray.
Dosage nasal spray.
Release form
Dosage nasal spray.
Packaging
vial 10 ml.
Pharmacological action
Antihistamine, selectively blocks H1-histamine receptors. Reduces the severity of allergic reactions mediated by the action of histamine.
Quickly eliminates the symptoms of allergic rhinitis (sneezing, itching in the nose, rhinorrhea) and improves nasal breathing (by reducing swelling of the nasal mucosa).
No carcinogenic and mutagenic effects or effects on fertility.
In doses exceeding 2500 times recommended for humans, it has teratogenic activity (increases the frequency of embryo resorption).
Indications
Allergic rhinitis, hay fever.
Contraindications
- children under 6 years old
- hypersensitivity to the components of the drug Tizinlerji.
Caution is advised to administer the drug to patients with impaired renal function and elderly patients.
Pregnancy and lactation
There are no reliable data on the use of Tizin® Allergy Nasal Spray in pregnant women.
Therefore, the drug should not be used during pregnancy unless the intended benefit to the mother justifies the potential risk to the fetus.
Based on the determination of the concentration of levocabastine in the saliva and breast milk of lactating women who received a single dose of 0.5 mg of levocabastine once, it is expected that approximately 0.6% of the total intranasal dose of levocabastine can be ingested by breastfeeding.
If necessary, the appointment of the drug during lactation should stop breastfeeding.
Special instructions
Effect on driving ability and driving mechanisms
The drug Tizin Allerji at the recommended dose usually does not have a clinically pronounced sedative effect and does not reduce the speed of the reaction compared with placebo.
In the event of drowsiness, the use of the drug should not engage in potentially hazardous activities that require increased attention and speed of psychomotor reactions.
Disposal considerations:
The patient must be informed that if the medicine is unusable or has expired, it should not be thrown into wastewater or into the street.
You must put the medicine in a bag and put it in a garbage container. These measures will help protect the environment.
Composition
Dosage nasal spray.
1 ml: levocabastine hydrochloride 540 mcg, respectively the content of levocabastine 500 ?g
Excipients:
propylene glycol - 48.26 ?l,
sodium hydrogen phosphate - 8.66 mg,
sodium hydrogen phosphate monohydrate - 5.38 mg,
hypromellose (2910 5 mPa.s) - 2.5 mg srd 1 ppm srd benzalkonium chloride - 150 ?g (as a 50% solution - 30 ?l),
disodium edetate - 150 ?g,
water for injection - up to 1 ml.
Dosage and administration
Intranasally administered to adults and children 6 years of age and 2 doses (100 mcg) in each nasal passage 2 times / day. The use of the drug should be continued until the symptoms are eliminated.
With more severe symptoms, Tizin Alergi can be used 3-4 times / day.
The patient should be warned about the need to clean the nasal cavity before using the spray and inhale through the nose during administration.
Before first use, remove the protective cap and press the spray nozzle several times until a cloud of mist appears. The bottle is ready for further use. The drug is inhaled through the nose.
Shake the bottle before each use.
Side effects of
Adverse events that were observed in? 1% of patients during clinical trials of
Digestive system: nausea.
From the nervous system: headache, drowsiness, dizziness.
From the respiratory system: pain in the pharynx and larynx, nosebleeds, cough.
Other: fatigue, pain at the injection site.
Adverse reactions that were noted
From the side of the respiratory system: short-term local irritation, pain at the injection site, dryness, burning, discomfort in the nasal cavity.
Post-marketing data:
Determination of the frequency of adverse reactions: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000, <1/100), rarely (> 1 / 10,000, <1/1000), very rarely (<1/10 000, including isolated cases).
From the cardiovascular system: rarely - tachycardia.
From the side of the immune system: infrequently - allergic reactions.
From the respiratory system: rarely - swelling of the nasal mucosa infrequently - shortness of breath frequency unknown - bronchospasm.
Other: infrequently - malaise frequency unknown - swelling of the eyelids.
Overdose
No reports of overdose of levocabastine.
Symptoms: with accidental ingestion, a decrease in blood pressure, tachycardia, a small sedative effect are possible.
Treatment: if taken orally, the patient should drink plenty of fluids to speed up the excretion of levocabastine by the kidneys.
Storage Conditions
The product should be stored out of the reach of children at a temperature not exceeding 25 РC.
Expiration
2 years.
Terms leave through pharmacies
without prescription
lekarstvennaja form
spray nazaln y
Janssen Pharmaceutical N.V., Belgium
Dosage nasal spray.
Packaging
vial 10 ml.
Pharmacological action
Antihistamine, selectively blocks H1-histamine receptors. Reduces the severity of allergic reactions mediated by the action of histamine.
Quickly eliminates the symptoms of allergic rhinitis (sneezing, itching in the nose, rhinorrhea) and improves nasal breathing (by reducing swelling of the nasal mucosa).
No carcinogenic and mutagenic effects or effects on fertility.
In doses exceeding 2500 times recommended for humans, it has teratogenic activity (increases the frequency of embryo resorption).
Indications
Allergic rhinitis, hay fever.
Contraindications
- children under 6 years old
- hypersensitivity to the components of the drug Tizinlerji.
Caution is advised to administer the drug to patients with impaired renal function and elderly patients.
Pregnancy and lactation
There are no reliable data on the use of Tizin® Allergy Nasal Spray in pregnant women.
Therefore, the drug should not be used during pregnancy unless the intended benefit to the mother justifies the potential risk to the fetus.
Based on the determination of the concentration of levocabastine in the saliva and breast milk of lactating women who received a single dose of 0.5 mg of levocabastine once, it is expected that approximately 0.6% of the total intranasal dose of levocabastine can be ingested by breastfeeding.
If necessary, the appointment of the drug during lactation should stop breastfeeding.
Special instructions
Effect on driving ability and driving mechanisms
The drug Tizin Allerji at the recommended dose usually does not have a clinically pronounced sedative effect and does not reduce the speed of the reaction compared with placebo.
In the event of drowsiness, the use of the drug should not engage in potentially hazardous activities that require increased attention and speed of psychomotor reactions.
Disposal considerations:
The patient must be informed that if the medicine is unusable or has expired, it should not be thrown into wastewater or into the street.
You must put the medicine in a bag and put it in a garbage container. These measures will help protect the environment.
Composition
Dosage nasal spray.
1 ml: levocabastine hydrochloride 540 mcg, respectively the content of levocabastine 500 ?g
Excipients:
propylene glycol - 48.26 ?l,
sodium hydrogen phosphate - 8.66 mg,
sodium hydrogen phosphate monohydrate - 5.38 mg,
hypromellose (2910 5 mPa.s) - 2.5 mg srd 1 ppm srd benzalkonium chloride - 150 ?g (as a 50% solution - 30 ?l),
disodium edetate - 150 ?g,
water for injection - up to 1 ml.
Dosage and administration
Intranasally administered to adults and children 6 years of age and 2 doses (100 mcg) in each nasal passage 2 times / day. The use of the drug should be continued until the symptoms are eliminated.
With more severe symptoms, Tizin Alergi can be used 3-4 times / day.
The patient should be warned about the need to clean the nasal cavity before using the spray and inhale through the nose during administration.
Before first use, remove the protective cap and press the spray nozzle several times until a cloud of mist appears. The bottle is ready for further use. The drug is inhaled through the nose.
Shake the bottle before each use.
Side effects of
Adverse events that were observed in? 1% of patients during clinical trials of
Digestive system: nausea.
From the nervous system: headache, drowsiness, dizziness.
From the respiratory system: pain in the pharynx and larynx, nosebleeds, cough.
Other: fatigue, pain at the injection site.
Adverse reactions that were noted
From the side of the respiratory system: short-term local irritation, pain at the injection site, dryness, burning, discomfort in the nasal cavity.
Post-marketing data:
Determination of the frequency of adverse reactions: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000, <1/100), rarely (> 1 / 10,000, <1/1000), very rarely (<1/10 000, including isolated cases).
From the cardiovascular system: rarely - tachycardia.
From the side of the immune system: infrequently - allergic reactions.
From the respiratory system: rarely - swelling of the nasal mucosa infrequently - shortness of breath frequency unknown - bronchospasm.
Other: infrequently - malaise frequency unknown - swelling of the eyelids.
Overdose
No reports of overdose of levocabastine.
Symptoms: with accidental ingestion, a decrease in blood pressure, tachycardia, a small sedative effect are possible.
Treatment: if taken orally, the patient should drink plenty of fluids to speed up the excretion of levocabastine by the kidneys.
Storage Conditions
The product should be stored out of the reach of children at a temperature not exceeding 25 РC.
Expiration
2 years.
Terms leave through pharmacies
without prescription
lekarstvennaja form
spray nazaln y
Janssen Pharmaceutical N.V., Belgium
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review